Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.36 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12423921 | 1.00 | CACNA2D1 (0.36) | CACNA2D1CACNA1BCACNB1CACNA1CATM | |
| SCHEMBL12423925 | 1.00 | CACNA2D1 (0.36) | CACNA2D1CACNA1BCACNB1CACNA1CATM | |
| SCHEMBL23707078 | 1.00 | CACNA2D1 (0.36) | CACNA2D1CACNA1BCACNB1CACNA1CATM | |
| SCHEMBL16903336 | 0.94 | KAT2B (0.34) | CACNA2D1CACNA1BCACNB1CACNA1CATM | |
| SCHEMBL7513512 | 0.86 | — | — | |
| SCHEMBL18685936 | 0.84 | CACNA2D1 (0.37) | CACNA2D1CACNA1BCACNB1CACNA1CATM | |
| SCHEMBL22479915 | 0.83 | CACNA2D1 (0.35) | CACNA2D1CACNA1BCACNB1CACNA1CATM | |
| SCHEMBL15837593 | 0.82 | CACNA2D1 (0.35) | CACNA2D1CACNA1BCACNB1CACNA1CATM | |
| SCHEMBL462404 | 0.82 | CACNA2D1 (0.35) | CACNA2D1CACNA1BCACNB1CACNA1CATM | |
| SCHEMBL463378 | 0.82 | CACNA2D1 (0.35) | CACNA2D1CACNA1BCACNB1CACNA1CATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024059951-A1 | INHIBITORS OF THE ANDROGEN RECEPTOR DNA-BINDING DOMAIN | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2024-03-28 | — | — | WO | disclosed |
| US-7709476-B2 | Isoquinolinone potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-05-04 | — | — | US | disclosed |
| US-20080227778-A1 | Isoquinolinone Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2008-09-18 | — | — | US | disclosed |
| US-5716954-A | ANTIINFLAMMATORY AGENT, ANTIHISTAMINES, IMMUNOSUPPRESSION,AUTOIMMUNE DISEASES | SYNTEX U.S.A. INC. (US) | 1998-02-10 | — | — | US | disclosed |
| EP-0612321-A1 | PYRIDO PYRIDAZINONE AND PYRIDAZINTHIONE COMPOUNDS WITH PDE IV INHIBITING ACTIVITY | SYNTEX (U.S.A.) INC. (US) | 1994-08-31 | — | — | EP | disclosed |
| WO-1993007146-A1 | BENZO AND PYRIDO PYRIDAZINONE AND PYRIDAZINTHIONE COMPOUNDS WITH PDE IV INHIBITING ACTIVITY | SYNTEX (U.S.A.) INC. (US) | 1993-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227778-A1 | Isoquinolinone Potassium Channel Inhibitors | KCNJ2, KCNQ1, KCNQ2 | CACNA2D1 140/4885CACNA1B 61/4885CACNB1 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.